Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review

This publication has 36 references indexed in Scilit:

• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
  The Lancet, 2012
• Characterising the castration-resistant prostate cancer population: a systematic review
  International Journal Of Clinical Practice, 2011
• Abiraterone and Increased Survival in Metastatic Prostate Cancer
  New England Journal of Medicine, 2011
• American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer
  Journal of Clinical Oncology, 2007
• A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
  Cancer, 2007
• Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
  Journal of Clinical Oncology, 2007
• Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group
  BMC Cancer, 2006
• Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
  Journal of Clinical Oncology, 2006
• Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer
  Journal of Clinical Oncology, 2005
• Clinical states in prostate cancer: toward a dynamic model of disease progression
  Urology, 2000